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ROLE OF ADJUVANT  STEROID THERAPY IN PATIENTS WITH 
SINONASAL POLYPOSIS 
 
INTRODUCTION 
  Chronic rhinosinusitis with Sinonasal Polyposis is a common problem that 
exacts a high cost in terms of direct health care as well as lost productivity1.The 
common pathophysiologic denominator for virtually all forms of Chronic 
RhinoSinusitis (CRS) is inflammation, for which extensive pharmacotherapy is 
available including topical corticosteroids, antibiotics, saline irrigations and 
systemic steroids. Unfortunately, not all patients are cured or achieve control of 
their symptoms even with maximal pharmacotherapy. In these patients who have 
failed medical management, endoscopic sinus surgery(ESS) has been demonstrated 
and is generally accepted to provide improved relief of symptoms and better 
quality of life3.  
ESS is a commonly performed procedure, with an estimated 1000 
procedures performed annually in our institute-Upgraded Institute of 
Otorhinolaryngology in Madras Medical College in Chennai. Although there is 
some controversy as to the best or most appropriate surgical technique for treating 
patients with Chronic Rhinosinusitis with Sinonasal polyposis (CRSwP)5 most 
surgeons will recommend that these patients undergo polypectomy6, complete 
ethmoidectomy, and middle meatal antrostomy, with or without frontal sinusotomy 
or sphenoidotomy. However, there is significant variability and a lack of 
standardization or guidelines4 with respect to the preparation and peri-operative 
pharmacotherapy regimen and management for patients undergoing ESS for 
CRSwP. 
In particular, some surgeons advocate the use of preoperative systemic 
steroids, citing such advantages as facilitation of the surgical procedure by 
reducing edema, polyp load, and bleeding. The theoretic advantages of peri-
operative steroids often cited include reduced edema and scarring postoperatively 
as well as suppression of the intrinsic inflammatory disease to permit better healing 
and better outcomes2. Relevant to this discussion is the fact that systemic steroids 
have been well described to have a litany of potential side effects, ranging from 
nuisance short-term problems such as mood disturbance and fluid retention, to 
moderate effects such as gastric irritation, to devastating side effects such as 
osteonecrosis of the femoral head12. Therefore, given that some surgeons advocate 
the use of peri-operative systemic steroids whereas others do not. The study design 
developed  to assess surgical outcomes is  placebo-controlled and seeks to assess 
specific surgical outcomes7 at the time of surgery as well as subjective and 
objective outcomes in the short and intermediate postoperative period. 
 In this study 50 cases of chronic rhinosinusitis with sinonasal polyposis is 
taken.25 cases were given peri-operative systemic steroids and the rest 25 were 
given placebo drugs peri-operatively. Operative and clinical data were collected 
and analyzed critically. 
 
 
 
 
 
 
 
 
 
 
 
 
AIMS OF THE STUDY 
The primary objective of the study is to assess the effect of peri-operative 
systemic corticosteroids on both subjective and objective outcomes in patients 
undergoing ESS for treatment of CRSwP. The primary measure of subjective 
change is the Sinus Symptom Questionnaire (SSQ) from the Lund-McKay staging 
system.13 The measure of objective change is the Lund-Kennedy Endoscopy Scale 
(LKES).14 Consequently, the primary objective of the study can be stated as three 
specific sub-objectives, as follow.  
Objective 1. 
 To assess the effect of peri-operative prednisone versus placebo with 
respect to operative parameters of the technical aspects of surgery- 
a) duration of surgery 
b) amount of blood loss during surgery 
c) health of mucosa 
d) disease clearance,that is the no.of sinuses opened 
Objective 2. 
 To assess the effect of peri-operative prednisone versus placebo with respect to 
changes in the six subscales of the SSQ.The parameters include- 
 a)facial pain 
b)headache 
c)nasal block 
d)nasal discharge 
e)olfactory disturbances 
f)overall discomfort. 
 Objective 3.  
To assess the effect of peri-operative prednisone versus placebo with respect 
to changes in the total LKES-Lund-Kennedy Endoscopy Score post-operatively at 
6 months.The parameters include- 
a) post op scarring 
b) post-op crusting 
c) recurrent polyps 
 
 
 
 
 
REVIEW OF LITERATURE 
CHRONIC RHINOSINUSITIS: 
 Epidemiology 
Chronic Rhinosinusitis with Sinonasal Polyposis is an inflammatory disease 
of the sinonasal tract that is of multifactorial etiology and complex classification. It 
occurs spontaneously in isolation but also is a relatively common co-manifestation 
of diseases such as  chronic asthma7, allergic rhinitis7, cystic fibrosis8, and 
inflammatory bowel8 disease.  
Traditionally discounted as a relatively benign condition, it has warranted 
increasing attention in recent years as awareness has grown of the significant 
societal impact it has. This impact relates not only to its relatively high prevalence, 
for example, affecting up to 16% of adults in the United States, 17%in the United 
Kingdom, and 13.5%in Canada, 22% of patients in India, 24% of patients in our 
Out Patient Department, but also to the significant effect it has on patient quality of 
life  and the economic burden it places on society, both in terms of direct health 
care costs and indirect costs secondary to loss of productivity.  
In one study, 22 adult patients were studied prospectively. CRS caused an 
average of 4.8 days of missed work per 12-month period. The overall yearly 
economic cost of CRS was estimated at$1,539 per patient. These costs amount to 
billions of rupees in direct costs each year in addition to the estimated 250,000 
endoscopic ethmoidectomies performed each year in the United States10. Thus, 
CRS is a common disease that exacts a significant toll on society in terms of direct 
costs and lost productivity, for which hundreds of thousands of patients undergo 
surgical treatment each year. 
ANATOMY OF THE PARANASAL SINUSES.               .    
 
 
MAXILLARY SINUS 
Structure 
 The adult maxillary sinus is a pyramid which has a volume of approximately 
15 ml (34x33x23mm).  The base of the pyramid is the nasal wall with the peak 
pointing toward the zygomatic process.  The anterior wall  has the infraorbital 
foramen located at the midsuperior portion with the infraorbital nerve running over 
the roof of the sinus and exiting through the foramen.  This nerve can be dehiscent 
(14%).  The thinnest portion of the anterior wall is just above the canine tooth--the 
canine fossa.  The roof is formed by the orbital floor and transected by the course 
of the infraorbital nerve.  The posterior wall is unremarkable.  Behind this wall  is 
the pterygomaxillary fossa with the internal maxillary artery, sphenopalatine 
ganglion and the Vidian canal, the greater palatine nerve and the foramen 
rotundum.  The floor, as discussed above, varies in its level.  From birth to age 
nine the floor of the sinus is above that of the nasal cavity.  At age nine the floor is 
generally at the level of the nasal floor.  The floor continues to sink as the 
maxillary sinus pneumatizes.  Because of the close relationship with the dentition 
dental disease can cause maxillary infection, and tooth extraction can result in oral-
antral fistulae.   
Vascular supply 
 Branches of the internal maxillary artery supply this sinus.  These include 
the infraorbital (as it runs with the infraorbital nerve), lateral branches of the 
sphenopalatine, greater palatine, and the alveolar arteries.  Venous drainage runs 
anteriorly into the facial vein and posteriorly into the maxillary vein and jugular vs. 
dural sinus systems.   
Innervation 
 The maxillary sinus is innervated by branches of V2.  Specifically, the 
greater palatine nerve and the branches of the infraorbital nerve. 
Related structures 
Nasolacrimal duct 
 The nasolacrimal duct drains the lacrimal sac and runs from the lacrimal 
fossa in the orbit down the posterior aspect of the maxillary vertical buttress and 
empties in the anterior aspect of the inferior meatus.  The duct lies very close to the 
maxillary ostium.  On average it lies 4mm-9mm anterior to the ostium. 
Natural ostium 
 The natural maxillary ostium is located at the superior aspect of the medial 
wall of the sinus.  Intranasally, it is usually in the posterior half of the ethmoid 
infundibulum, or behind the lower 1/3 of the uncinate process.  The posterior edge 
of the ostia is continuous with the lamina papyracea, thus a reliable landmark for 
the lateral limit of surgical dissection.  The ostium size averages 2.4 mm but can 
vary from 1 to 17mm.  The ostium is much smaller than that actual bony defect, as 
mucosa fills this area and defines the extent of the opening.  88% of maxillary 
ostium are hidden behind the uncinate process and therefore cannot be visualized 
endoscopically.   
Anterior/Posterior Fontanelles/Accessory Ostium 
 Two bony dehiscences of the lateral nasal wall/maxillary sinus medial wall 
exist (sometimes there is one large bone dehiscence.  These are usually covered by 
mucosa.  In some individuals the anterior or posterior fontanelles may be patent 
which results in an accessory ostium.  They are nonfunctional ostia and serve to 
drain the sinus only if the natural ostium is blocked and intrasinus pressure/gravity 
moves material out of the ostium.  Accessory ostium are usually found in the 
posterior fontanel.  
ETHMOID SINUSES 
Structure 
Posterior and anterior cells combined have a volume of 15 ml 
(3.3x2.7x1.4cm).  The ethmoids are shaped like a pyramid and are divided into 
multiple cells by thin septa.  The roof of the ethmoids is composed of multiple 
important structures.  The roof slopes both posteriorly (angle of 15 degrees) and 
medially.  The anterior 2/3 of the roof is thick and strong and is composed of the 
frontal bone and the fovea ethmoidalis.  The posterior 1/3 is higher laterally and 
slopes down medially to the cribiform plate.  The junction between the lateral 
dense bone and the plate is one-tenth as strong as the lateral roof.  The difference 
in height between the lateral and medial roof is variable, but can be as much as 15-
17mm.  The posterior aspect of the ethmoid cells borders on the sphenoid sinus.  
The lateral wall is the lamina papyracea of the orbit. 
Vascular supply 
 The ethmoid sinuses are supplied by blood flow originating from both the 
external and internal carotid arteries.  The Sphenopalatine artery as well as the 
ophthalmic artery (which branches into the anterior and posterior ethmoid arteries) 
supply the sinus.  Venous drainage follows arterial supply and thus can track 
infection intracranially. 
 
Innervation 
 Both V1 and V2 innervate this region.  V1 supplies the more superior aspect 
with V2 innervating the inferior regions.  Parasympathetic innervation is via the 
Vidian nerve.  Sympathetic innervation is via the cervical sympathetic ganglion 
and follows the arterial vasculature to the mucosa of the sinuses. 
Related structures 
Basal Lamella (Ground Lamella) of the Middle Turbinate 
 This structure forms the separation between the anterior and posterior 
ethmoid cells.  It is the attachment of the middle turbinate and runs in three 
different planes in its course from anterior to posterior.  The anterior most portion 
is vertical and inserts in the crista ethmoidalis and skull base.  The middle third is 
oblique with insertion in the lamina papyracea.  The final third runs horizontal with 
insertion in the lamina papyracea.  The space under the middle turbinate is termed 
the middle meatus into which the anterior ethmoids, frontal sinus, and maxillary 
sinus drain.  Surgical damage to the anterior or posterior portions of the middle 
turbinate may destabilize this structure and anteriorly risks disruption of the 
cribiform plate. 
Anterior vs. posterior Ethmoid cells 
 The anterior cells are those anterior to the basal lamella.  They drain into the 
middle meatus via the ethmoid infundibulum.  They include the agger nasi cells, 
the ethmoid bulla and any other anterior cells.  The posterior cells drain into the 
superior meatus and border on the sphenoid sinus.  They are generally fewer in 
number and larger than the anterior cells.   
Agger nasi cell 
 The cell is found in the lacrimal bone anterior and superior to the junction of 
the middle turbinate with the nasal wall (often described as the bulge in the lateral 
nasal wall where the middle turbinate attaches).  It is hidden behind the anterior 
most aspect of the uncinate process and drains into the hiatus semilunaris.  It is the 
first cell to pneumatize in the newborn and is prominent through childhood.  There 
can be from one to three cells.  The posterior wall of the cell forms the anterior 
wall of the frontal recess.  The roof of the agger nasi cell is the floor of the frontal 
sinus, and is therefore, an important landmark for frontal sinus surgery. 
Ethmoid Bulla 
 This is the most constant landmark for surgery.  It lies above the 
infundibulum and its lateral/inferior surface and the superior edge of the uncinate 
process forms the hiatus semilunaris.  It is usually the largest of the anterior 
ethmoid cells.  The anterior ethmoid artery usually courses across the roof of this 
cell.  Suprabullar and retrobullar recesses may be formed when the ethmoid bulla 
does not extend to the skull base.  The suprabullar recess is when there is a cleft 
between the roof of the ethmoid bulla and the fovea.  The retrobullar space is 
formed when there is a cleft between the basal lamella and bulla.  This retrobullar 
space opens into what is known as the "hiatus semilunaris superior." 
Ethmoid infundibulum 
 The development of the infundibulum precedes that of the sinuses.  This 
recess, into which the anterior ethmoid sinuses, maxillary sinus and frontal sinus 
drain, is formed by multiple structures.  The anterior wall is formed by the uncinate 
process, the medial wall is the frontal process of the maxilla and the lamina 
papyracea.  It runs anteriorly in continuity with the frontal recess to its posterior 
limit where the uncinate process attaches to the lamina.  The opening above the 
recess is known as the hiatus semilunaris.  The maxillary sinus is found in this 
area. 
Anterior/Posterior Ethmoid Arteries 
The anterior and posterior ethmoid arteries arise from the ophthalmic artery 
in the orbit.  The anterior artery crosses the medial rectus and penetrates the lamina 
papyracea.  The artery then courses across the roof the ethmoid sinus in a thin bony 
mesentery (usually dehiscent), eventually supplying the cribiform plate and 
anterior septum.  This artery is usually large and singular and may drape inferiorly 
into a sinus cell.  Its position closely corresponds to the position of the more 
medial structure, ethmoidal fovea.  The posterior artery crosses the medial rectus, 
penetrates the lamina papyracea and courses through the posterior ethmoid cells 
(usually corresponding with the anterior wall of the posterior-most cell) to the 
septum.  It supplies the posterior ethmoid sinuses, part of the superior and middle 
turbinates and small amount of the posterior septum.  This artery is usually smaller 
and branched.  It can be dehiscent and drape down within the sinus cells.  Its 
position is associated with the position of the optic nerve near the orbital vertex.  
Because the development of these structures predate the sinuses their relation to 
the ethmoid cells can vary.  Their association with the fovea and optic nerve 
remain constant.                                                                    .  
OSTEOMEATAL COMPLEX AND DRAINAGE OF PARANASAL 
SINUSES 
FRONTAL SINUS 
Structure 
 The volume of the sinus is approximately 6-7 ml (28x24x20mm).  Frontal 
sinus anatomy is highly variable, but generally there are two sinuses which are 
funnel shaped and point upward.  The depth of the sinus is the most surgically 
significant dimension as it determines the limitations of surgical approach.  Both 
frontal sinuses have their ostia at the most dependant portion of the cavity 
(posteriomedial).  Many feel this is the reason that these sinuses are rarely involved 
with infectious disease.  Both the anterior and posterior walls of this sinus are 
composed of diploeic bone.  However, the posterior wall (separates the frontal 
sinus from the anterior cranial fossa) is much thinner.  The floor of the sinus also 
functions as a portion of the orbital roof. 
Vascular supply 
 The frontal sinus is supplied by the ophthalmic artery via the supraorbital 
and supratroclear arteries.  Venous drainage is via the superior ophthalmic veins to 
the cavernous sinus and via small venulae in the posterior wall which drains to the 
dural sinuses. 
Innervation 
 The frontal sinus is innervated by branches of V1.  Specifically, these nerves 
include the supraorbital and supratrochlear branches. 
Related structures 
Frontal recess 
 The frontal recess is the space between the frontal sinus and the hiatus 
semilunaris into which the sinus drains.  It is bounded anteriorly by the agger nasi 
cell and superiorly by the frontal sinus, medially by the middle turbinate, and 
laterally by the lamina papyracea.  The cavity resembles a dumbbell as the frontal 
sinus narrows to the sinus ostium/channel and then opens again into the wider 
frontal recess.  Depending on the extent of ethmoid pneumatization, this recess can 
become tubular resulting in a much longer narrowing of the dumbbell.  Anomalous 
structures, such as the sinus lateralis (posterior to the frontal recess at the skull 
base) and frontal bulla (anterior to the recess at the base of the frontal sinus) may 
be mistaken as the frontal sinus during sinus surgery. 
ISPHENOD SINUS 
StructureIn the late teen years the sinus reaches its full size with a volume of 7.5 
ml (23x20x17mm).  Pneumatization of this sinus, like that of the frontal sinus, is 
very variable.  Generally these are bilateral structures located at the 
posterosuperior aspect of the nasal cavity.  Pneumatization can extend as far as the 
clivus, the sphenoid wings, and the foramen magnum.  The walls of the sphenoid 
vary in thickness with the anterosuperior wall and roof being the thinnest (.1 to 1.5 
mm).  The other walls are thicker.  The thinnest part of the anterior wall is 1cm 
from the fovea ethmoidalis. The position of the sinus and, therefore, its anatomic 
relationships depend on the extent of pneumatization.  The sinus can sit far anterior 
to, just anterior to, or immediately under the sella tursica (conchal, presellar, 
sellar/postsellar).  The most posterior position can place the sinus just adjacent to 
vital structures such as the carotid arteries, optic nerves, maxillary branch of the 
trigeminal nerve, the Vidian nerve, the pons, sella tursica, and the cavernous sinus.  
These structures are often identified as indentions on the roof and walls of the 
sinus.  A small percentage will have dehiscence of bone over such vital structures 
as the optic nerve and carotid arteries.  Care must also be taken when removing 
sinus septa as these may be in continuity with the carotid and optic canal and can 
result in death and blindness.   
The sphenoid sinus ostium drains into the sphenoethmoidal recess.  The 
ostium is very small (.5-4mm) and is located about 10mm above the sinus floor.  A 
30 degree angle drawn from the anterior nasal floor approximates the location of 
the ostium on the posterosuperior nasal wall.  It is noted to be close to the midline 
at the junction of the upper 1/3 and the lower 2/3 of the anterior sinus wall.  It is 
generally medial to the supreme/superior turbinate, and is only a few millimeters 
from the cribiform plate.  This ostium, like that of the maxillary sinus, has a much 
larger bony dehiscence which is narrowed by a membranous septum.     
Vascular supply 
The posterior ethmoid artery supplies the roof of the sphenoid sinus.  The 
rest of the sinus is supplied by the sphenopalatine artery.  Venous drainage is via 
the maxillary veins to the jugular and pterygoid plexus systems. 
Innervation 
 The sphenoid sinus is supplied by branches from both V1 and V2.  The 
nasociliary nerve (from V1) runs into the posterior ethmoid nerve and supplies the 
roof.  The branches of the sphenopalatine nerve (V2) supply the floor. 
Related structures 
Sphenoethmoidal recess 
 The sphenoethmoid recess is a space behind and above the most superior 
turbinate.  The boundaries of this space are formed by multiple structures.  The 
anterior wall of the sphenoid sinus forms the posterior aspect.  The nasal septum 
and cribiform plate form the medial and superior aspects.  The anterolateral extent 
is determined by the most superior turbinate.  The space opens into the nasal cavity 
inferiorly.  The posterior ethmoid cells, as well as the sphenoid sinus empty into 
this region. 
Sphenoid rostrum 
This structure is simply the midline projection of the anterior sphenoid sinus wall.  
It articulates with the perpendicular plate and the vomer. 
Onodi cell 
 As discussed above, these cells are ethmoid cells which are located 
anterolateral to the sphenoid sinus.  Vital structures such as the carotid artery and 
optic nerve may run through this cell.  These structures are often dehiscent.  This 
requires careful dissection in this area and good preoperative radiographic 
examination to avoid poor outcomes. 
MICROSCOPIC ANATOMY.                                         . 
     
The sinuses are lined with pseudostratified ciliated columnar epithelium which is 
in continuity with the mucosa of the nasal cavities.  The epithelium of the sinuses 
is thinner than that of the nose.  There are four basic cell types.  These include 
ciliated columnar epithelial cells, nonciliated columnar cells, basal cells, and goblet 
cells.  The ciliated cells have 50-200 cilia per cell with the usual structure of  9+2 
microtubules  with dynein arms.  Experimental data shows these cells to beat at 
700-800 times a minute, moving mucus at a rate of 9 mm/minute.  Nonciliated 
cells are characterized by microvilli which cover the apical aspect of the cell and 
serve to increase surface area (likely to facilitate humidification and warming of 
inspired air).  It is interesting to note that there is an increased concentration (up to 
50%) at the sinus ostium.  The basal cell's function is unknown.  They vary in size, 
shape and number.  Some have theorized that they serve as a stem cell which can 
differentiate as needed.  Goblet cells produce glycoproteins which are responsible 
for the viscosity and elasticity of mucus.  They are innervated by the 
parasympathetic and sympathetic nervous system.  Thus, parasympathetic 
stimulation induces thicker mucus with sympathetic stimulation leading to more 
watery mucus secretion.   
The epithelial layer is supported by a thin basement membrane, lamina 
propria, and periosteum.  Both serous and mucinous glands tract down into the 
lamina propria.  Anatomic studies have shown a general paucity of goblet cells and 
submucosal glands in the sinuses compared to the nasal mucosa.  When comparing 
the sinuses, the maxillary sinus has the highest density of goblet cells.  The ostia of 
the maxillary, sphenoid, and anterior ethmoid sinuses seem to have an increased 
number of submucosal serous and mucinous glands. 
MUCOCILIARY CLEARANCE.                    .                     
.  
The ciliated cells in each sinus beat in a specific direction. A resulting 
pattern of mucus flow results.  Since many of the sinuses develop in an outward 
and inferiorly fashion, the ciliated mucosa often moves material against gravity to 
the sinus' exit.  This means that mucus produced just adjacent to a sinus ostia, if it 
is on the afferent side, will travel around the entire sinus cavity, often against 
gravity, before exiting the ostia.  This is one reason that creation of accessory ostia 
at sites outside the physiologic ostium will not significantly improve sinus 
drainage.  In fact, this sometimes results in mucus draining from the natural ostia 
reentering the sinus via the newly created opening and cycling through the sinus 
again.  Hilding was the first that described each sinuses' mucus flow patterns, and 
his observations are still valid today.  Later researchers described a phenomenon of 
stagnation which occurs when two ciliated surfaces come into contact (particularly 
applicable at the osteomeatal complex).  This disrupts mucociliary mucus 
clearance and can result in sinusitis.  Clearance of the disease is accomplished 
when this clearance mechanism has been restored. 
SINUS FUNCTION 
The physiology and function of the sinuses has been the subject of much 
research.  Unfortunately, we still are unsure as to all the functions of these air-
filled spaces.  Multiple theories of function exist.  These include the functions of 
warming/humidification of air, assisting in regulation of intranasal pressure and 
serum gas pressures (and subsequently minute ventilation), contributing to immune 
defense, increasing mucosal surface area, lightening the skull, giving resonance to 
the voice, absorbing shock, and contributing to facial growth.  The nose is an 
amazing humidifier and warmer of air.  Even at seven liters/minute of airflow, the 
nose has not reached its maximal ability to perform this function.  Nasal 
humidification has been shown to contribute as much as 6.9 mm Hg on serum pO2.  
Although the nasal mucosa is best adapted to perform this task, the sinuses 
contribute to mucosal surface area and warming ability.  Some researchers have 
shown that mouth breathers have a decreased end-tidal CO2 which may increase 
serum CO2 and contribute to sleep apnea.   
Because of the sinuses' copious mucous production they contribute heavily 
to the immune defense/air filtration performed by the nose.  The nasal and sinus 
mucosa is ciliated and functions to move mucus to the choanae and the stomach 
beyond.  The thickened superficial layer of nasal mucus serves to trap bacteria and 
particulate matter in a substance rich with immune cells, antibodies, and 
antibacterial proteins.  The underlying sol layer is much thinner and serves to 
provide a thinner substrate in which the cilia are able to beat; their tips essentially 
grabbing the superficial layer and pushing it in the direction of the beat.  Unless 
obstructed by disease or anatomical variance, the sinuses move mucous through 
their cavities and out of their ostia toward the choane.  The most recent research on 
sinus function has focused on the molecule Nitrous Oxide (N2O).  Studies have 
shown that the production of intranasal N2O is primarily in the sinuses.  N2O has 
been shown to be toxic to bacteria, fungi, and viruses at levels as low as 100 ppb.  
Nasal concentrations of this substance can reach 30,000 ppb which some 
researchers have theorized as the mechanism of sinus sterilization.  N2O has also 
been shown to increase ciliary motility.   
The physiology and function of the paranasal sinuses is a subject that 
reflects the complexity of their anatomy.  Continued research may likely reveal 
that all of these functions are part of a bigger, more involved picture than is now 
apparent. 
Etiology of CRS 
The precipitating cause of CRS remains elusive in many cases. As stated 
above, it frequently is seen in association with chronic asthma, with rhinitis 
occurring in approximately 75%of allergic asthmatics and asthma developing in 
20%of those with seasonal allergic rhinitis11. Moreover, co-morbidity with asthma 
is associated with worse endoscopic evidence of rhinosinusitis  and a less 
satisfactory response to endoscopic surgical management 
 Sampter’s triad consists of nasal polyposis, asthma and aspirin intolerance. 
A common thread through asthma and polyposis is the presence of eosinophilia, 
which, similar to asthma, is associated both with more severe endoscopic evidence 
of sinusitis and a poorer response to treatment. Eosinophilia also is associated with 
nasal polyposis, both with and without CRS15. CRSwP, inturn, is associated with 
greater symptoms and overall worse disease than CRS without polyposis. The 
above described findings have led many authors to conclude that these seemingly 
disparate respiratory tract inflammatory conditions are, in many cases, actually 
manifestations of one common systemic disease. 
 One currently popular theory regarding the association between CRSwP, 
asthma, and eosinophilia is that a chronic inflammatory response occurs in 
response to bacterial superantigens. Also, more than one research group recently 
has identified the presence of bacterial biofilms within the sinuses, which may 
serve as a trigger for the chronic inflammatory response16.  
In cases of CRS without polyposis, chronic bacterial infection has been 
implicated as an etiologic factor. In contrast with acute bacterial rhinosinusitis, a 
higher incidence of Staphylococci has been described in CRS, including 
methicillin-resistant Staph aureus . However, numerous other bacteria have been 
cultured from the sinuses of patients undergoing endoscopic treatment of CRS, 
including the more common organisms such as Haemophilus influenzae, 
Streptococcus pneumoniae25,and Moraxella catarrhalis25.Other common pathogens, 
particularly in patients who have undergone previous surgery, include 
Pseudomonas aeruginosa and hemolytic streptococci. Moreover, one group has 
identified a higher prevalence of Helicobacter pylori than expected among 
individuals with nasal polyposis16. 
 In contrast, other studies have failed to support a bacterial role in CRS 
causation. In one of these studies, positive cultures at the time of surgery were no 
different between patients with and without polyposis, and in the absence of gross 
purulence visible endoscopically, some authors question the utility of antibiotics at 
all 25.  
Antibiotics do appear to have some beneficial effect in the management of 
non-infectious CRS, but this generally pertains to them macrolide agents, which 
have been suggested to possess significant anti-inflammatory attributes. This anti-
inflammatory role for macrolides has held variable degrees of favour in recent 
years.  
 Fungal infections commonly are associated with local and systemic 
eosinophilia. These findings have led investigators in recent years to suggest a role 
for fungi in the pathogenesis of CRS and nasal polyposis. These authors have 
found fungus to be ubiquitous on sinonasal culture using highly sensitive 
techniques and propose the theory that the afflicted patient populations react in an 
exaggerated fashion to these fungal antigens as compared with nonafflicted people. 
Again, however, the evidence is inconclusive and debate continues25. 
 Other risk factors for the development of CRS are air pollution and chronic 
cigarette use. Other diseases associated with sinonasal polyposis include  
9 cystic fibrosis25 
9 allergic fungal sinusitis25 
9 Kartagener’s syndrome-bronchiectasis, situs inversus & ciliary 
dyskinesis 25 
9 Young’s syndrome-sinopulmonary disease & azoospermia 25  
9 Nasal mastocytosis25 and  
9 Churg-Strauss syndrome25. 
Pathophysiology of CRS with Polyposis  
As stated above, the mechanisms by which CRS and nasal polyposis develop 
are not entirely understood. However, considerable evidence suggests that both 
conditions result from chronic inflammation with resultant tissue hyperplasia18.   
Stammberger evaluated nasal polyps in 200 consecutive patients undergoing 
functional endoscopic sinus surgery. He noted that 80% polyps originated from the 
middle meatal mucosa, uncinate process and infundibulum. In 65%, polyps 
originated from the ethmoidal bulla and hiatus semilunaris and from the frontal 
recess in 48%. Polyps were found inside the bulla in 30%3. 
Nasal mucosa particularly in the region of osteomeatal complex becomes 
oedematous due to collection of extra-cellular fluid causing polypoidal change. 
Polypi which are sessile in the beginning become pedunculated due to gravity and 
excessive sneezing especially in allergic patients3.  
Nasal polyps usually have a respiratory epithelium with ciliated columnar 
and goblet cells. Squamous metaplasia can occur due to exposure and repeated 
trauma. Gross edema will lead to artifact when polyps are processed under electron 
microscopy.3 
As the polyp shrinks the surface epithelium is lost to a variable extent and is 
described as “cobble-stones”. There is apparent thickening of basement membrane. 
The submucosal tissue is grossly edematous and contains few blood vessels and 
occasional nerve fibres.The cellular infiltrate is mainly plasma cells, small 
lymphocytes, macrophages and most striking feature is eosinophilia3. Eosinophils 
are found in 90% of polyps, the majority of the remaining cells in other polyps are 
neutrophils. Sensitized eosinophils are important in the initiation of mucosal edema 
in patients with aspirin hypersensitivity. In fact, eosinophilia often is apparent, 
both systemically and locally, within inflamed nasal mucosa and within polyps 
themselves. However, eosinophilia is not always present.  
In one study in which biopsies were obtained from the inferior turbinates of 
14 patients with nonallergic CRS versus 10 healthy controls, significant increases 
(P .05) were detected in numbers of CD3, CD4, and CD8 Tcells and Bcells in the 
nasal mucosa of patients with CRS25. 
 In another study, 29 adults with refractory chronic sinusitis underwent 
functional ESS (FESS) after standard preoperative computed tomography (CT). 
Six patients with normal sinus mucosa served as control subjects. Patients were 
subdivided into two groups according to their dominant pathologic features: 16 had 
polypoid mucosa and peripheral eosinophilia, and 13 had glandular hyperplasia. 
The numbers of eosinophils, and of T and B lymphocytes in the lamina propria, 
were significantly higher in patients with polypoid mucosa and eosinophilia versus 
those with glandular hyperplasia and versus normal control subjects, whereas the 
differences between patients with glandular hyperplasia and control subjects were 
insignificant. 
 Although the overall inflammatory reaction was relatively modest, nasal 
polyposis was more prevalent in patients with polypoid mucosa and eosinophilia; 
likewise, CT revealed significantly more extensive disease in these patients versus 
those with glandular hyperplasia. It can be concluded from this evidence that most 
patients with polyposis appear to have a more intense, and potentially systemic, 
inflammatory response associated with inflammatory cells, including eosinophils. 
Results from these two studies suggest that there may be more than one 
overall mechanism by which CRS and nasal polyposis develop. At least one such 
mechanism is associated with significant eosinophilia, immunoglobin  E 
production, and atopy. Another appears to be non-allergic, associated more with T-
lymphocyte and neutrophil predominance. Various subsets of T lymphocytes 
appear to be more important than others in the pathologic process of CRS, with or 
without nasal polyposis. The number of CD4 cells consistently was higher than the 
number of CD8 cells, and CD4T-helper cells appeared to be especially 
predominant 25 in the initiation and regulation of inflammation 
 In another study involving 12 patients with CRS and polyposis, both local 
and systemic influx of CD4 lymphocytes was evident in response to 
Staphylococcal exotoxins25, including inflammation within the polyps themselves, 
prompting these and other investigators to conjecture that CD4 cells present 
Staphylococcal  or other infectious super-antigens as an initiating and propagating 
step in the development of CRS and associated polyps. Eosinophilia also has been 
observed as a response to Staphylococcal super-antigens, and both eosinophils and 
T lymphocytes appear in the setting of a diverse array of cytokines so as to 
accentuate and perpetuate the inflammatory response.  
Recent research suggests that a chemokine called25 RANTES (regulated on 
activation, normal T-cell-expressed, and secreted), a member of the CC chemokine 
family with chemotactic activity directed primarily toward eosinophils and T 
lymphocytes, may be very important in the recruitment of eosinophils and T 
lymphocytes into the nose in patients with CRS and nasal polyposis. Several 
additional chemokines such as eotaxin and monocyte chemotactic proteins have 
also been implicated as contributing factors in the development of eosinophilia in 
CRSwP  
Hyperplasia of  tissue, secondary to the local inflammatory response, results 
in a variety of  the symptoms and complications of CRS, including polyposis. 
Mucin 25 gene up-regulation probably is responsible for the mucus hypersecretion 
that can be so clinically prominent and problematic. 
 It can thus be seen from the previous summary that CRS is a complex 
disease with multiple proposed etiologies. Significant progress is being made with 
respect to our understanding of the molecular and immunopathologic mechanisms 
that underlie this disease, the common denominator of which is an intense, 
perpetuated inflammatory process, which drives the formation of polyps and 
hyperplastic mucosa. It is this inflammatory process26 that is also the target of 
virtually all forms of therapy currently available to clinicians treating patient with 
CRS. 
Clinical Presentation of Disease  
CRS, with or without nasal polyposis, is associated with a myriad of clinical 
symptoms that commonly include facial pain or pressure; facial congestion or 
fullness; nasal congestion or obstruction; rhinorrhea; hyposmia or anosmia; low-
grade fever; chronic cough; headache; halitosis; fatigue; dental pain; and ear 
pressure or pain21.  
Of these various symptoms, the most common major symptoms are nasal 
obstruction, observed in 94% of patients; facial congestions-(85%); and nasal 
discharge (82%); the most common minor symptom is headache, observed in 83%.  
           
Fig 7 : Endoscopic Picture of Sinonasal Polyps 
 
1.            
                         Fig 8 : Endoscopic Picture of Sinonasal Polyps 
The Rhinosinusitis Consensus Research Definitions and Clinical Trial 
Guidelines list four different categories of sinusitis: recurrent acute sinusitis; 
CRSwP; CRS without    polyposis; and classic allergic fungal sinusitis. 
Consequently, different sets of classification criteria have been created, primarily 
distinguishing acute bacterial rhinosinusitis from other types of rhinosinusitis22. 
Both include lists of major and minor symptoms, and both have requirements for at 
least two major criteria or one major and two minor criteria for a diagnosis of 
probable rhinosinusitis. 
 Both criteria sets include purulent anterior nasal drainage and purulent 
posterior drainage as major symptoms. Most of the other symptoms listed above 
are given largely as minor criteria for acute rhinosinusitis or some as major and 
others as minor criteria for rhinosinusitis, acute or chronic. This paper and research 
study focus on CRS  rather than acute or allergic fungal sinusitis and, in particular, 
on CRSwP25.  
Nonsurgical Management of CRS and Nasal Polyposis 
 ESS or FESS generally is reserved for patients with CRS, with or without 
nasal polyposis, who are refractory to maximal medical management. However, 
this subgroup constitutes the minority of patients. Most patients respond to one or a 
combination of treatments that may include-Maximal Medical Therapy(MMT) 
with antihistamines, nasal decongestants, antibiotics, and corticosteroids-both 
topical and systemic, Mast cell stabilizers, Mucoevacuants, Leukotriene 
antagonists, immunotherapy and other supportive management like optimal 
nutrition, steam inhalation, nasal irrigation, allergic desensitization and avoiding 
environmental ancitants4.  
Of these, antibiotics and corticosteroids have warranted the greatest research 
interest. Although the microbiology of purulent CRS is well documented, the 
treatment of this condition is not easily based on solid evidence. There is fairly 
solid evidence that endoscopically guided cultures can be helpful in identifying 
offending organisms in CRS ,and using this information23 to direct antimicrobial 
therapy is a commonly accepted practice. 
 The most recent guidelines addressing the issue of therapy selection and 
duration still recommend 4to 6weeksof uninterrupted therapy for CRS. When 
chosen for use, a variety of different antibiotic regimens have been touted as 
effective, including amoxicillin/clavulanicacid , the macrolides (such as 
clarithromycin), ciprofloxacin and newer fluoroquinolones and 
trimethoprim/sulfamethoxazole24. Although usually taken orally, some treatment 
regimens warrant intravenous or intranasal delivery of these drugs.  
However, in general, clinical trials involving antibiotics have been small, or 
noncontrolled, or of short duration, and relapse rates have been as high as 89%. 
Moreover, the use of antibiotics is not without the risk of complications. 
Intravenous antibiotics are prone to a variety of catheter related complications, 
albeit in a small minority and all antibiotics carry the risk of drug reactions and the 
development of resistance. In patients who have failed more traditional medical 
regimens, potentially including CRS associated with chronic purulence, selective 
irrigation of the sinuses with a solution containing antibiotics and corticosteroids 
has shown potential. 
 Perhaps the most interesting and novel evidence supporting the benefit of 
antibiotics involved a study of mucociliary clearance in patients treated with 
antibiotics for CRS.  
The respiratory tract is lined by an epithelium comprising mucus producing 
cells and ciliated cells that serves as the first line of defense in the upper and lower 
respiratory tracts. Failure of mucociliary clearance is associated with chronic or 
recurrent respiratory tract infection25. Prolonged antibiotic use can help to restore 
mucociliary system function.  
Although antibiotics are generally thought to be of benefit through their 
antimicrobial properties, which reduce bacterial infection and its associated host 
inflammatory response, considerable work has examined the anti-
inflammatory/immunomodulatory effects of the macolides, an effect that may be 
more important in CRS than their antimicrobial effect. Clarithromycin, in 
particular, has been demonstrated to have a variety of immunosuppressant effects, 
including in vitro reduction in the cellular production25 of transforming growth 
factor-beta and nuclear factor-kappa B and of interleukin-5, interleukin-8, and 
granulocyte-macrophage colony-stimulating factor. In fact, some authors are 
currently recommending macrolide therapy as a standard part of maximal medical 
therapy prior to considering a patient as a candidate for ESS. 
 Further evidence supporting the value of immune- modulating therapy in 
CRS comes from a recent pilot study involving the use of interferon (IFN)-gamma. 
 In that study25, 10 patients with treatment resistant CRS  who had been 
treated with exogenous IFN- gamma (50g/m2) were evaluated by retrospective 
assessment of clinical outcomes compared with clinical and laboratory findings 
before IFN-gamma treatment. Prior to treatment, all 10 patients had been suspected 
of having deregulated IFN-gamma production. CRS in these patients was reported 
to be better controlled in all nine patients who received exogenous IFN-gamma for 
longer than 3 months.  
Thus it has been concluded that exogenous IFN-gamma maybe a therapeutic 
option in a subset of patients with treatment resistant CRS and evidence of 
deregulated IFN-gamma production. However, the greatest evidence both for the 
role of inflammation in the development and perpetuation of CRS and nasal 
polyposis and for the benefits of immune-modulating therapy stems from the 
apparent effectiveness of corticosteroids in the treatment of both conditions 
occurring singly or in combination.  
Corticosteroids in Medical Management of CRS and Nasal Polyposis  
  The evidence that topical corticosteroids have a beneficial effect in CRS and 
nasal polyposis is quite compelling.  
As early as 1994, a study of 11patients25 with CRS and nasal polyposis who 
had been treated for 1 month with the topical nasal steroid budesonide, 200 to 400 
g/day, and compared them with 10 untreated patients. Overall, it was found that 
most eosinophils in the examined nasal tissues were in the stoma layers and that 
the proportion of activated eosinophils was significantly lower in polyps from 
steroid-treated patients. Also, in the polyps from treated patients, the superficial 
stoma layer and deep stoma layer both contained significantly fewer CD3, CD4, 
and CD8 T lymphocytes.  
Subsequently, the benefit of various preparations of topical corticosteroids, 
such as betamethasone sodium phosphate nasal drops and beclomethasone 
dipropionate, fluticasone propionate, and budesonide nasal sprays, for CRS and 
nasal polyposis has been demonstrated in several randomized, placebo-controlled 
trials. 
The mechanism by which they work appears to be multifactorial, the effect 
being initiated by their binding to a specific cytoplasmic glucocorticoid receptor. 
At a cellular level, this results in a reduction in the number of antigen-presenting 
cells, in the number and degree of activation of Tcells, in number of mast cells, and 
in the number and degree of activation of eosinophils25. 
 Topical corticosteroids are of use in the primary treatment of nasal polyps 
when they are of a small or medium size, but surgery is generally required for 
larger polyps because of the resultant nasal obstruction and limited access for 
topical preparations. 
 Corticosteroids25 also have been suggested to reduce the need for ESS. 
Another study of 54 patients scheduled for ESS because of severe nasal polyposis, 
CRS, or both were included in a 12-week, double-blind, placebo- controlled study. 
Half of the subjects were randomized to receive fluticasone propionate nasal drops 
(FPND) in a concentrated form. Use of intranasal steroid spray was stopped at 
least 4 weeks before randomization. Signs and symptoms were recorded before, 
during, and at the end of the treatment period. At the end of the study, a CT scan 
was performed, and the need for operation was reassessed by means of a 
standardized scoring method. ESS no longer was required in 13 of 27 steroid-
treated patients.  
This study provides evidence of effectiveness for topical steroids delivered 
in an alternate form but did not provide effective management in all cases. Despite 
ample evidence that topical corticosteroids have efficacy in the preoperative 
medical management of rhinosinusitis, only recently have investigators started to 
look at the potential benefit of intranasal steroids postoperatively. The results have 
been mixed.   
One question that remains to be answered, and which is the focus of this 
paper, is the role of systemic corticosteroids peri-operatively in patients 
undergoing ESS. As discussed in the following section, ESS is believed to be a 
highly successful procedure, but it is associated with complications and a relatively 
high rate of recidivism, both of which might be alleviated, at least to some 
degree25, by the concurrent application of the potent anti-inflammatory properties 
corticosteroids induce. Also, in the following section, the value and merits of 
systemic steroids in the management of CRSwP will be discussed. 
 Endoscopic Sinus Surgery 
 ESS, sometimes called FESS, was first described in the North American 
scientific literature by Kennedy  in 1985. It was touted as an effective way of re-
establishing ventilation and mucociliary clearance of the sinuses, primarily by 
means of endoscopic removal of hypertrophic tissue and bone from key areas of 
the anterior ethmoid and middle meatus. In addition, sphenoethmoidectomy was 
possible while preserving the middle turbinate. 
 The technique afforded the advantage of excellent visualization, with 
relatively minimal trauma, bleeding, and overall morbidity, so much so that, in 
1994, Maran  wrote, "Endoscopic nasal surgery has become the single major 
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advance in the specialty of otolaryngology since the introduction of the operating 
microscope and middle ear surgery".25 Since that time, there have been numerous 
clinical studies demonstrating both the short-term and long-term benefits of ESS. 
These studies have documented improvement in a variety of parameters, from 
specific symptoms such as olfaction, to general health  and quality of life. ESS 
even appears to benefit the asthma that commonly accompanies CRS.  
 Various studies demonstrated that25 ESS was more effective at producing 
healthy sinus cavities than the radical Caldwell-Luc surgery. More recent studies 
have compared ESS in combination with various preparations of corticosteroids 
versus corticosteroids alone. There is evidence of the effectiveness of systemic 
steroids in the treatment of CRSwP and reinforces the widely held management 
principle that patients are only considered candidates for ESS when they have 
failed maximal medical therapy, generally including systemic steroids. The benefit 
of ESS in CRS, with or without polyposis, largely is accepted. 
 Most endoscopic sinus surgeons only would consider a patient to be a 
candidate for ESS after they have failed maximal medical therapy, in its current 
state of the art. As surgeons, we are always cognizant that the procedure itself is 
not without risks, and once the decision has been made that a patient will benefit 
from ESS, the surgeon always considers the potential downside of the 
intervention, in particular the potential complications. 
 Complications of ESS generally include potential orbital injuries, such as 
hematoma or extraocular muscle injuries, osteitis, and skull base injuries25. All of 
these complications, fortunately, are rare in experienced hands.  
Nonetheless, one of the potential advantages of peri-operative 
corticosteroids would be to reduce preoperative and intraoperative swelling and 
polyp load as well as reduce the degree of inflammation and, theoretically, blood 
flow or loss, thereby improving visualization of the surgical field and facilitating 
surgery and disease clearance. The use of corticosteroids peri-operatively, 
however, is unproven and not without potential risks of its own. 
 Peri-operative Management for ESS 
 Peri-operative medical therapy in patients undergoing ESS is believed by 
many to be important, although there is considerable variability in actual practice 
based on published  and survey data. Although many surgeons believe that routine 
post-operative care including endoscopic debridement optimizes surgical 
outcomes, the evidence is conflicting. 
 In fact, in one study25, 95.5% of 45 patients with refractory CRS achieved at 
least a 50% reduction in symptoms, despite a complete absence of post-operative 
care other than nasal douching with hypertonic saline after the 10th postoperative 
day. Consequently, the general consensus appears to be that some peri-operative 
management is indicated. 
 A significant body of literature exists examining various aspects of peri-
operative management, especially of postoperative management. These studies 
include clinical trials examining the effectiveness of peri-operative antibiotics; 
mitomycinC (MMC)25;  nasal packing;  various wound dressing materials;  the use 
of post-operative debridement; and counseling regarding cessation of smoking 
cigarettes. These studies have provided conflicting results.  
With respect to MMC, for example, Chungetal25., in a study of 55 patients 
undergoing bilateral ESS in whom a pledget soaked with 1 mL 0.04 mg/mL MMC 
randomly was applied to the infundibulum of one side and a similar pledget soaked 
in saline was applied to the other, unilateral adhesions were observed only in 
3.6%of the MMC sides versus 14.5%of the saline sides, a result that almost 
achieved statistical significance ( P .058). Conversely, in view of the unknown 
long-term risks of administering an antineoplastic agent for non-neoplastic disease, 
this therapy has not gained wide popularity.  
Peri-operative Corticosteroids for ESS  
As already indicated, corticosteroids, in one form or another, often are part 
of standard medical management, and this often is continued throughout the peri-
operative period and beyond in patients undergoing ESS. However, this is not 
without risks because systemic corticosteroids not only reduce inflammation, they 
also generally impair immune responses, delay wound healing, and predispose 
patients to a variety of potentially serious side effects, some of which may occur 
acutely.  
The rationale for their use in the peri-operative period, also as stated earlier, 
is that reduced inflammation in the operative field would intuitively be anticipated 
to improve visualization, reduce bleeding and related surgical complications, and 
result in improved healing, with less inflammation and less scarring. This all is 
unproven, however, which is the principal motivation behind the current study. 
 Mechanisms by Which Corticosteroids Work 
 Cortisone first was isolated from adrenal tissue by Mason et al.  in the 
1930s. It was Hench et al.,  however, who sparked interest in corticosteroids as a 
potential therapeutic agent, when they discovered their potent anti-inflammatory 
effects, a discovery that won these investigators a Nobel Prize in 1950. 
Unfortunately, it soon was discovered that the therapeutic use of corticosteroids 
was associated with a myriad of potential side effects, many quite unpleasant and 
many others potentially disfiguring or serious. 
 After years of trial and error, the current state of the art for steroid use is to 
use as low a dose as possible, for as short a time as possible. Nonetheless, their use 
continues, in some instances, because they are life or limb saving. Moreover, many 
conditions, by their very nature, require the chronic use of corticosteroids. Until 
very recently, for example, chronic use of corticosteroids was the only therapeutic 
option available for patients with polymyalgia rheumatica and giant cell arteritis25. 
 There is no question that, except for treating patients who are adrenal 
insufficient, the therapeutic benefits of corticosteroids almost exclusively stem 
from their potent anti-inflammatory and immunosuppressant effects. These effects 
certainly are what are thought to be of advantage in the treatment of CRS and nasal 
polyposis.  
The specific mechanisms by which corticosteroids work in general, or in 
particular in CRS and nasal polyposis, are unclear. What is known is that 
corticosteroids have a large variety of anti-inflammatory and immunosuppressant 
effects that inhibit both cascades at virtually all levels. They inhibit the migration 
of neutrophils and monocytes; presentation of antigen by macrophages to 
lymphocytes; lymphocyte proliferation, activation, and differentiation, and 
cytokine production and action.  Virtually all species of lymphocytes appear to be 
sensitive to these inhibitory effects, including the T-lymphocyte subsets that 
appear to be predominant in CRS.  
 Recalling that CRS and nasal polyposis are both often associated with 
significant local and occasional systemic eosinophilia, corticosteroids also are 
potent inhibitors of  eosinophils and have been used clinically to treat a variety of 
chronic inflammatory disorders associated with eosinophilia, including asthma,  
eosinophilia-myalgia syndrome, eosinophilic fasciitis, eosinophilic esophagitis, 
Churg-Strauss syndrome, hypereosinophilic syndrome,  and chronic eosinophilic 
pneumonia. The primary advantages of corticosteroids in the management of CRS 
and nasal polyposis, therefore, are their potent anti-inflammatory and anti-immune 
effects, their easy delivery, and their generally very low monetary cost.  
As stated earlier, the mucosal edema, friability, and tissue hypertrophy 
present in CRS and nasal polyposis may contribute to decreased visualization 
within the surgical field, more significant bleeding, and an increased risk of 
surgical mishaps. Consequently, reducing this swelling/tissue hypertrophy 
potentially could improve both the ease of the operation and the ultimate outcome. 
In addition, reduced inflammation in the post-operative period may improve 
longer-term surgical outcomes. That corticosteroids can be delivered intranasal by 
a variety of means, including sprays and drops, facilitates their use, reduces the 
risk of systemic side effects (especially if used in low doses and for shorter periods 
of time), and, likely, improves patient compliance.  
Risks of Corticosteroid Use 
 For all their many uses and potentially life-saving effects, perhaps only 
narcotics and cancer chemotherapeutic drugs inspire more trepidation than 
corticosteroids, and justifiably so. The list of potential corticosteroid related side 
effects is long and filled with many theoretically concerning effects, including25  
9 Cushing's syndrome  
9 weight gain 
9 truncal obesity  
9 hypertension 
9 various disfiguring skin changes 
9 diabetes mellitus 
9 increased risk of infections, including opportunistic infections  
9 myopathy 
9 osteoporosis 
9 peptic ulcer disease 
9 hyperlipoproteinemia and atherosclerosis 
9 mood and mental changes 
9 pancreatitis 
9 osteonecrosis.  
There are also a litany of short- term, nuisance side effects such as 
• mood disturbances 
• gastric irritation 
• fluid retention 
• increased appetite 
 which are reversible with cessation of the medications. With respect to their 
shorter, peri-operative use, however, perhaps the side effects of greatest relevance 
and potential concern are  
1) impaired wound healing  
2) immunosuppression with resultant increased infection risk  
3) osteonecrosis, particularly avascular necrosis of the femoral head in old age 
patients (hip) 
 Delayed wound healing- 
 That cortisone causes detrimental effects on wound healing became evident 
as early as 1950and 1951, when several different research groups published the 
results of their studies.  This is not surprising given the various skin manifestations 
observed with Cushing's syndrome, including skin atrophy and striae 
. The mechanisms of impaired wound healing appear to relate to the 
catabolic effects of cortisone and its analogs. These catabolic effects include 
protein breakdown; decreased new protein synthesis in various tissues including 
skin, muscle, bone, and connective tissue; and the inhibition of DNA synthesis and 
cell proliferation in various cell lines including fibroblasts. These all results in 
delayed formation of scar tissue and delayed epithelialization, an effect that can 
persist for up to 9 weeks, after the drug has been withdrawn25.  
There are, however, potential mechanisms by which this impairment in 
wound healing can be, at least partially, reversed, including the use of vitamin A, 
anabolic steroids, growth hormone, and the tetrachlorodecaoxygen anion complex.  
Despite this, the effect of intranasal steroids25 on wound healing never has been 
studied, nor have any studies addressed the potential effects of corticosteroids on 
wound healing in ESS. In fact, there are theoretic advantages to some impairment 
in wound healing with respect to the common dilemma of synechiae formation 
post-ESS.  
Increased risk of infection- 
 Corticosteroids primarily benefit humankind because of their anti-
inflammatory and immunosuppressive effects. However, as stated earlier, these 
effects are not targeted at anyone facet of the immune system or inflammatory 
pathway. 
 Corticosteroids globally inhibit both, which, at least theoretically, should 
result in an increase in the risk of infections. In fact, such an increase risk has been 
documented.  This is worthy of some consideration in the post-operative period, 
both because of the increased risk of infections post-operatively and because of the 
adverse healing effects that wound infections cause. 
 As pertains to ESS, one recent study undertook intraoperative cultures from 
the nasal vestibule, middle meatus, ethmoid lining, and peripheral blood during 
and after ESS in patients with CRS. The study found that approximately 30%of the 
patients had sterile sinuses, 50%had coagulase-negative staphylococci, and the 
remainder had a mixed group of "nonpathogenic"organisms. Anaerobes were 
conspicuously rare. In addition, blood cultures were positive in 7% of cases and 
were consistent with an organism already identified at the operative site.  
Whether an increase in infection risk would occur with the use of intranasal 
steroids is not clear. In general, lower doses of corticosteroids do not appear to 
increase infection risk,  and the short-term, peri-operative use of these medications 
in an otherwise immunocompetent host does not intuitively appear risky. So far, 
virtually all the research demonstrating an increased infection risk caused by 
corticosteroids was performed on patients with autoimmune rheumatic diseases, 
which are, in themselves,  associated with significant alterations in immune status, 
even untreated, and with an increased risk of infections.  That the same level of 
risk would occur in patients with CRS, even at higher doses of steroids, is unlikely, 
but not known. 
 One should recognize that, although relatively little intranasal drug25 is 
absorbed systemically, at least compared with oral preparations, nonetheless, there 
is some absorption via this route, a phenomenon that has led to the development of 
several intranasal delivered drugs for the treatment, for example, of refractory 
migraines. Moreover, even if the amount of steroid delivered systemically is 
relatively small and unlikely to precipitate systemic or peripheral infections, 
nonetheless, the risk of local infection and its effect on clinical outcome cannot be 
completely ignored.  
Nevertheless, it can be generally summarized that topical intranasal  steroids 
likely have an eligible risk of immune suppression, something that may not be the 
case with systemic steroids. 
 Osteonecrosis- 
  Avascular necrosis of the hip is one of the classic, acute catastrophic 
consequences of corticosteroid use, most commonly at higher doses.  Unlike 
osteoporosis, which only develops after at least 3 months of therapy and usually 
only after much longer than that, osteonecrosis has been observed as early as 7 
days after initiation of steroid therapy, albeit only very rarely and generally only 
with higher doses. Moreover,  steroid-induced osteonecrosis can involve both hips 
or several other joints as well, with involvement particularly in the femoral heads 
and condyles, the humeral heads.  Osteonecrosis of the hip has been subdivided 
into five clinical stages, numbered from 0 to IV, as part of the Association 
Research Circulation Osseous international classification criteria. 
 Early detection is important, most easily by means of magnetic resonance 
imaging(MRI). Treatment includes immediate cessation of steroids and supportive 
measures. Although traditional thinking holds that osteonecrosis develops 
secondary to a hypercoagulable state with impaired fibinolysis, recent evidence has 
suggested that corticosteroid induced adipogenesis in bone marrow may contribute 
to osteonecrosis and that the statin class of cholesterol lowering medications may 
be helpful in preventing steroid induced osteonecrosis.  Unfortunately, many 
patients with hip disease ultimately require total hip arthroplasties. Patients with 
involvement of other joints sometimes require joint fusion. 
 When corticosteroids are considered in the context of short-term use in 
patients with CRSwP, the literature does give one cause for reflection. To date, 
there are no data on the risk of osteonecrosis25 with intranasal use of steroids or 
with ESS. Clearly, systemic steroids have significant advantages in many disease 
states including CRS, but this is counterbalanced by the not insignificant 
associated side effects. Common sense on the part of clinicians as well as 
published recommendations propose that systemic corticosteroids be used in 
situations where the indications are solid, the evidence for their efficacy is 
accepted if not proven, and the medical co morbidities are taken into account.  
 
 
 
  
 
MATERIALS AND METHODS 
Patient Selection 
 The patient population chosen for study was that with CRSwP. This is the 
patient population within the Chronic Rhinosinusitis population that tends to be the 
most recalcitrant with respect to the recurrence of both objective and subjective 
findings postoperatively. It is also the population in which some surgeons are 
likely to use peri-operative systemic steroids7,11.  
Diagnostic Criteria  
Consistent with the most recent definitions recommended for clinical 
research into rhinosinusitis,15 the study population included patients with 
symptoms of mucopurulent nasal drainage, nasal obstruction and decreased sense 
of smell for greater than 12 weeks duration. Patients all underwent diagnostic 
nasal endoscopy to confirm the presence of nasal polyposis bilaterally as well as 
computed tomography (CT) scanning  to confirm  bilateral mucosal disease. No 
further sub-classification beyond CRSwP was performed, consistent with the 
current definitions and guidelines for research regarding patients  with 
rhinosinusitis.15 
Period of Study 
 June 2007-November 2008 
 In Upgraded Institute of Otorhinolaryngology 
Inclusion Criteria  
• Adult patients (over 18 yrs of age) scheduled to undergo ESS for 
treatment of their disease were offered the opportunity to participate in 
the study.  
• Upper age limit was 60 years.  
To become candidates for ESS, the patient either had to have failed maximal 
medical therapy. Maximal medical therapy for patients with CRSwP included 
prolonged trials of topical therapy for more than 3 months. Topical therapy was 
defined as intranasal steroids given twice daily and saline irrigations. Antibiotics in 
the form of a 4 to 6 week course were used as appropriate as based on the 
endoscopic findings and endoscopically guided culture results rather than on an 
empiric basis. 
 Exclusion Criteria 
9 Age < 18 years 
9 Age > 60 years 
9 Patients with Diabetes Mellitus 
9 Patients with Hypertension 
9 Patients with immunocompromised status and mucociliary disorders 
were excluded.    
9 Patients with allergic fungal rhinosinusitis (AFRS) were excluded 
from the study. This was done preoperatively based on the classic 
endoscopic findings of allergic mucin and the presence of classic CT 
scan findings. Presence of classic allergic mucin with Charcot-Leyden 
crystals and fungal hyphae constituted the diagnosis of AFRS, and the 
patient was not included in the study population 
. Experimental Design  
To assess the impact of peri-operative systemic steroids on surgical 
outcomes in patients with CRSwP, a randomized, placebo-controlled study was 
designed. Once patients were determined to meet the inclusion criteria for the 
study, they were randomized to receive either placebo or systemic steroids for 7 
days preoperatively and 14 days postoperatively and then stopped in a tapering 
dose. The dose used was 30 mg taken as the entire daily dose in the morning .The 
moderate dose chosen (30 mg) for this study was believed to be sufficient for 
effective clinical activity and to mitigate the potential undesirable short-term side 
effects associated with higher doses (e.g., 50-60 mg). Active medication and 
placebo-multivitamin tablets- were externally identical in terms of tablet 
preparation. Patients continued the medication after surgery for 2 weeks. Both the 
cases and placebo group were given topical steroids post-operatively.  Follow-up 
done in the post-op period till 6 months. 
Surgical Technique 
 ESS was performed using the Messerklinger technique as described by 
Kennedy.16 Mucosal preservation and preservation of normal structures was 
attempted in all cases. All the cases were attempted to give maximum disease 
clearance. Packing materials were used as necessary for hemostasis or stenting and 
generally consisted of Merocel and Ivalon  sponges when used. Decongestant 
Otrivin (xylometazoline) drops were advised for 3-5 days post-operatively. All 
patients were placed on nasal douching and saline sprays post-operatively as well 
as postoperative antibiotics  for a  period of 2 weeks. They resumed their topical 
intranasal steroid sprays after nasal douching . 
 Data Collection Points 
 Baseline surgical data collected with the help of anaesthetist and surgeon 
 Patients were routinely seen on postoperative days 2 to 4 for removal of the 
packing or stenting materials. They were then seen at 2weeks postoperatively for 
endoscopic inspection and debridement of the ethmoid cavities. Patients were 
insisted to have regular follow up. Data were collected post-operatively during the 
follow-up and at the end of 6 months.   
Sample Size  
A sample size of 50 has been taken. 
25 cases and 25 controls 
Ethics Approval  
Institutional Ethical Committee ,Government General Hospital & Madras 
Medical College, Chennai reviewed the experimental design and protocol as well 
as the letter of information and the consent form. Full approval of the board was 
granted under protocol number K.Dis.No.16328P &D3/Ethics/Dean/GGH/08. All 
patients were given information outlining the experimental protocol and all 
patients signed a consent form prior to entering the study. 
 Data Collection  
Data were first collected regarding the surgery itself and its relative 
difficulty including the health and state of the sinonasal mucosa. In terms of 
postoperative data, two additional primary outcomes were identified, namely, 
subjective assessment of the impact of the disease on the patient (i.e., symptoms) 
as well as objective data in the form of nasal endoscopy. 
Operative Data  
Duration of the procedure and estimated blood loss, were all recorded. Also 
noted at the time of surgery was the health of the nasal and turbinate mucosa. A 3-
point scale (healthy 1, inflamed/erythematous 2, severely inflamed/ friable3) was 
used for this measurement. Finally, the disease clearance and the no.of sinuses 
opened is estimated by the surgeon.  
Subjective Outcomes 
 In choosing a subjective grading scheme, the historically reliable, disease-
specific Lund-MacKay SSQ was used13 The reasoning for this choice was 
reproducibility, reliability and demonstrated validity. In addition ,the results are 
easy to interpret and record with minimal burden to the study participant. It was 
also believed to be useful for assessing disease activity overtime and thought to be 
responsive to change.15 Thus, a visual analogue scale (VAS) that measures from 0 
(symptom not present) to 10 (extremely severe) was used to assess the six 
symptoms of nasal blockage/congestion, headache, facial pain, olfactory loss, nasal 
discharge/postnasal drip, and overall discomfort. 
Objective Outcomes  
Nasal endoscopy was included as the single most important outcome 
measure of disease activity in this study. The objective nature of the assessment 
with direct inspection of the sinus cavities helped to avoid the potential 
unreliability of patient symptoms as an estimate of the disease, particularly in the 
early stages of recurrence. Nasal endoscopy is an excellent way to assess disease 
presence and severity. The Lund-Kennedy  nasal endoscopy scoring system was 
used.14 Crusting and scarring including synechiae formation  are graded as absent 
(0), mild (1), or extensive (2). Mucosal edema when severe will lead into or border 
on polypoid change. Polypoid change would be scored as whether present or 
absent. 
 Statistical Analysis 
 All data were collected and entered into a standard statistical package . Standard 
demographic summaries were generated, and routine comparisons were made 
using both univariate chi-square test.  
 
 
 
 
 
  
 
 
 
 OBSERVATION AND RESULTS 
The current study is a randomized, placebo-controlled study examining the 
effect of peri-operative systemic steroids on surgical outcomes in patients 
undergoing ESS for treatment of CRSwP. Both subjective and objective outcomes 
measures were used. The primary objective of the study was to assess, in a detailed 
fashion, the effect of the steroids on these subjective and objective outcomes.  
.Impact of Systemic Steroids on Technical Aspects of Surgery  
A frequent justification for the use of systemic steroids preoperatively in 
patients undergoing ESS for treatment of CRSwP is that it will facilitate the 
surgery.11 The rationale includes less bleeding, better visualization, and less trauma 
to the tissues. This study therefore sought to provide some evidence to support 
what is, at best, expert opinion only and not uniformly practiced.7 The findings of 
this study demonstrate that there is a clinically significant difference detected in 
the technical difficulty of surgery. 
In this study, the median value of duration of surgery in the test group is 60 
minutes where as in the placebo group it is 110 minutes as shown in table1.Mean 
average in the test group is 70 minutes where as in placebo group it is 97.6 minutes 
1. Duration of Surgery-fig :1&2 
 
 
 
  
 
 
 
 
   
                                       
 
 
 
 
Test minimum 40 
 maximum 120 
median 60 
Control minimum 55 
 maximum 130 
 median 55 
The use of peri-operative steroids has dramatically reduced the amount of 
blood loss during surgery. The mean average of amount of blood loss in the test 
group is 128 ml where as among the placebo group it is 164 ml. The bloodless field 
might have had significant influence on decreasing the duration of surgery as 
already seen in table 1. In the test group only 28% had severe (~200ml) blood loss 
using surgery where as in placebo group 64% had severe bleeding on table as 
shown below.                                                    . 
 
2. Estimated Blood Loss-fig :3 
 
 
 
Table 2: Blood loss
18 72.0 72.0 72.0
7 28.0 28.0 100.0
25 100.0 100.0
9 36.0 36.0 36.0
16 64.0 64.0 100.0
25 100.0 100.0
100
200
Total
Valid
100
200
Total
Valid
Test/control
test
control
Frequency Percent Valid Percent
Cumulative
Percent
 
 
3. Health of  Mucosa-fig :4 
            
 
 
Furthermore, patients who did not receive preoperative systemic steroids 
were far more likely to have sinonasal mucosa rated as friable in32% cases, 
inflamed mucosa in 24% cases and healthy mucosa in 44% cases. On the contrary  
in the test group sinonasal mucosa were rate as friable in only 8% cases, inflamed 
mucosa in 12% cases and healthy mucosa in 80% cases. This is shown in table  3. 
.  
These differences were rated as significantly important clinically and this 
might have contributed to the operative ease during surgery in test group. This 
gross difference  shows the anti-inflammatory efficacy of steroids in cases of 
sinonasal polyposis. 
It is to be noted that maximum disease clearance could only be given in 
cases treated peri-operatively  with steroids. All the sinuses-Maxillary, Ethmoids, 
Frontal and sphenoid sinuses-were cleared of the disease in all the cases in test 
group. In the placebo group, all sinuses could be opened only in 20% cases as 
                                    Table 3: Health of mucosa
20 80.0 80.0 80.0
3 12.0 12.0 92.0
2 8.0 8.0 100.0
25 100.0 100.0
11 44.0 44.0 44.0
6 24.0 24.0 68.0
8 32.0 32.0 100.0
25 100.0 100.0
healthy
inflamed
friable
Total
Valid
healthy
inflamed
friable
Total
Valid
Test/control
test
control
Frequency Percent Valid Percent
Cumulative
Percent
shown in table 4                                                    .        
 
In all the other cases in placebo group, surgeon was not satisfied about the 
disease clearance. In those cases surgery was restricted only to maxillary and 
ethmoid sinuses due to absence of adequate visualization and severe bleeding. 
 Finally, it is noteworthy that the two variables, duration of surgery, blood 
loss , mucosal health and the disease clearance which can be linked. 
 Impact of Steroids on Subjective Outcomes (Symptoms)  
The impact of ESS on subjective outcomes for both groups was 
demonstrated in this study to be clinically significant at 6 weeks postoperatively. 
 
On analyzing the symptoms post-operatively maximum improvement was 
seen with nasal block. The patients who were given adjuvant steroid therapy peri-
7
5
5
36
8
6
9
9
7
7
45
Valid
Missing
N
Median
Minimum
Maximum
Valid
Missing
N
Median
Minimum
Maximum
Test/control
test
control
Facial pain
score
Headache
score Nasal block
Nasal
discharge
olfactory
disturbance
overall
discomfort total score
Table4: No. of Sinuses opened
25 100.0 100.0 100.0
13 52.0 52.0 52.0
7 28.0 28.0 80.0
5 20.0 20.0 100.0
25 100.0 100.0
8Valid
4
6
8
Total
Valid
Test/control
test
control
Frequency Percent Valid Percent
Cumulative
Percent
operatively has only a median score of 2 for nasal block where as the placebo 
group showed a median score of  8.This is shown in table 5. This can be explained 
well with the complete disease clearance in the test group.   
This difference could also be appreciated in the improvement of olfactory 
disturbance and over-all discomfort score note in the test group. As shown in  table 
5, median score for olfactory disturbance is 3 in the test group where as  it is 6 in 
the placebo group. The same is seen with over-all discomfort score.  This can also 
b explained well with the complete disease clearance in the test group and also the 
absence of post-op scarring, crusting and recurrence which is described later      
       There is also noticeable difference in the median score of facial pain among 
the test and the placebo group. As shown in table 5 it is 4 in the test group where as 
it is 7 in the placebo group. The same difference would  be  seen with median score 
for nasal discharge .It is 4 in the test group and 8 in the control group. This is 
shown in table 8.  
The only symptom score which does not show much difference between test 
group and placebo group is median score for headache. It is 5 in the placebo group 
and 4 in the test group. This is shown in table 5. This may b due to intermingling 
or blending of other causes of headache. 
And the total symptom score shows  significant difference among both 
groups. Median total symptom score in the test group is 20 where as the total 
3. Subjective outcome-Visual Analogue Scoring-fig :5 
 
 
 
4. Objective Outcome-Lund Kennedy Endoscopic Scoring-fig :6 
 
  
symptom score among the control group is 40 .This proves the  efficiency of peri-
operative administration of steroids in the subjective outcome.  
Impact of Steroids on Objective Outcomes (Endoscopy) 
  With use of the Lund-Mackay endoscopic scoring system to compare 
patients, there were significant improvements noted at most time points for the 
prednisone group but not for the placebo-treated groups. Thus, the patients 
receiving prednisone had clinically significant healthier cavities.  
In the test group post-operative scarring and synechiae formation is absent in 
84% cases where as there was scarring in the placebo group in 60% cases. This is  
shown in table 6.  
:  
This impact is due to the anti-inflammatory effect of corticosteroid peri-
operatively. The less tissue injury due to healthy mucosa an less duration of 
surgery among the test group might also have contributed to decrease the incidence 
of scarring.  
Table 6: post-op scaring
21 84.0 84.0 84.0
2 8.0 8.0 92.0
2 8.0 8.0 100.0
25 100.0 100.0
10 40.0 40.0 40.0
8 32.0 32.0 72.0
7 28.0 28.0 100.0
25 100.0 100.0
absent
mild
severe
Total
Valid
absent
mild
severe
Total
Valid
Test/control
test
control
Frequency Percent Valid Percent
Cumulative
Percent
The same effect is seen with post-operative crusting also. This is  shown in table7. 
In the test group there was no crusting in 76% of cases where as there was 
noticeable crusting  in 60% of the placebo group. This also shows the efficacy of 
anti-inflammatory action of steroids.  
 
The incidence of recurrence is also more among the placebo group. 
Recurrent polyps were seen in 4% of cases in  the test group where as it was 32% 
in the placebo group as shown in table 8. 
  
The recurrence was assessed at the end of 6 months. If an endoscopic 
follow-up is done at 2 years or later this value might increase. The increase 
recurrence rate among the placebo group can be attributed to the incomplete 
clearance of the disease as already explained in table 4. 
Table 8: Recurrent polyps
24 96.0 96.0 96.0
1 4.0 4.0 100.0
25 100.0 100.0
17 68.0 68.0 68.0
8 32.0 32.0 100.0
25 100.0 100.0
absent
mild
Total
Valid
absent
mild
Total
Valid
Test/control
test
control
Frequency Percent Valid Percent
Cumulative
Percent
Table 7: post-op crusting
19 76.0 76.0 76.0
3 12.0 12.0 88.0
3 12.0 12.0 100.0
25 100.0 100.0
10 40.0 40.0 40.0
7 28.0 28.0 68.0
8 32.0 32.0 100.0
25 100.0 100.0
absent
mild
severe
Total
Valid
absent
mild
severe
Total
Valid
Test/control
test
control
Frequency Percent Valid Percent
Cumulative
Percent
                                 Fig 11: Post-op Picture                                                           
 
                  Fig 12 : Post-op Picture after 6 months             
 
      DISCUSSION 
The treatment of Chronic Rhinosinusitis with Sinonasal Polyposis is 
Endoscopic Polypectomy. This has been well proven over many years. But the role 
of corticosteroids an its administration is debatable over many years. In this study 
this debate has taken into the topic of study. 
 Systemic steroids can be given as tablets –prednisolone –as we administered 
in this study or as depot injections. The total glucocorticoid dose in a depot 
injection corresponds to about 100 mg prednisolone. When given orally the dose is 
30 mg  prednisolone daily for 3 weeks. However controlled dose effect studies are 
not available.  
 Lildholt3 has described that a short course of systemic steroid is equally 
effective as simple polypectomy with a snare and it may serve as medical 
polypectomy. This study also proves the above observation. In severe disease 
requiring endoscopic surgery, pre-operative use of steroid will considerably 
facilitate surgery. This is proven in this study. Adverse effects from this therapy 
cannot be expected to be severe and may be outweighed by increased quality  of 
life in patients with severe disease an abolished fashion3 
 Intranasal steroids are by far the best documented type of treatment for 
Sinonasal polyposis. There are at least 16 placebo controlled studies and they have 
all shown a significant effect. Some patients do not respond  to topical steroids. 
This may be due to inadequate intranasal distribution of spray in a very blocked 
nose. Here comes the importance of  Endoscopic polypectomy. 
 Intranasal steroids an systemic steroids will not eliminate the polyps, but the 
treatment clearly reduces the size and decrease the inflammatory activity of 
mucosa and thus facilitate surgery. On the other hand, an effect on polyps in the 
middle meatus cannot be expected as only a small fraction of spray reaches the 
middle meatus. So these critical areas should be opened during surgery to facilitate 
good ventilation of the sinuses. In this study in the placebo group, the number of 
sinuses opened surgically was actually lower than planned, an effect not observed 
with the prednisolone group. As noted by the surgeon, this difference was not 
caused by the absence of disease in the unopened sinuses, but rather was limited by 
technical issues primarily related to visualization and bleeding. With respect to the 
health of sinonasal mucosa as assessed at the time of surgery, there was a 
significant difference between groups, with the placebo group having a much 
higher incidence of friable an inflamed mucosa compare with the test group.     
 Controlled studies have shown that topical steroids can delay the recurrence 
of polyps after surgery. However the effect is partial especially in cases of 
pronounced inflammatory activity. 
CONCLUSION AND SUMMARY 
Based on the data collected and analyzed in this study, several conclusions 
can be drawn as related to the study objectives. 
 First, pretreatment with systemic steroids appears to confer the advantages 
of facilitating surgery, by opening up all the diseased sinuses; and clearing the 
disease and improving the health of  the sinonasal mucosa and minimizing the 
bleeding thus decreasing the duration of surgery. Therefore, in the context of 
evidence-based practice, there is sufficient evidence to support the preoperative 
administration of systemic steroids to all patients undergoing ESS for CRSwP. 
 Second, treatment postoperatively with systemic steroids results in better 
symptom relief especially nasal obstruction, loss of smell, facial pain, nasal 
discharge, headache and overall discomfort. 
Third, the treatment with systemic steroids in the immediate post-operative 
period results in endoscopically healthier sinus cavities in the short term, an 
outcome of relevance if the goal of sinus surgery for these patients is to achieve an 
endoscopically healthy sinonasal cavity in the long term. Thus, in the practice of 
surgeons who provide intensive postoperative care for patients post- ESS, 
including debridement and medical therapy, as based on the endoscopic findings, 
there is evidence to support administering systemic steroids in the postoperative 
period in an effort to optimize the initial endoscopic appearance of the cavities 
Lastly, the peri-operative administration of  adjuvant steroids are also 
beneficial to prevent  the post-operative complications like post-op scarring, 
synechiae formation, post-op  crusting and to prevent recurrence. 
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ABBREVIATIONS 
 
• CRS        Æ Chronic RhinoSinusitis 
• ESS         Æ Endoscopic Sinus Surgery 
• CRSwP   Æ Chronic Rhinosinusitis with Sinonasal Polyposis 
• V1           Æ Ophthalmic branch of  Trigeminal Nerve 
• V2           Æ Maxillary branch of Trigeminal Nerve. 
• pO2         Æ Partial pressure of Oxygen 
• CO2        Æ Carbon Dioxide 
• N2O        Æ Nitrous Oxide 
• FESS      Æ Functional Endoscopic Sinus Surgery 
• CT          Æ Computed Tomography 
• RANTESÆ Regulated on Activation, normal T-cell expressed , and secreted 
• MMT      Æ Maximal Medical Therapy 
• IFN         Æ Interferon 
• MBP       Æ Major Basic Protein 
• MMC      Æ Mitomycin C 
• MRI        Æ Magnetic Resonance Imaging 
• AFS        Æ Allergic Fungal Sinusitis 
• SSQ        Æ Sinus Symptom Questionare 
• VAS        Æ Visual Analogue Scale 
• LKES     Æ Lund Kennedy Endoscopic Scoring 
